Clinical Trials
53 trialsINTerpath-007
Merck Sharp & Dohme LLC
IL Believe
Ascendis Pharma A/S
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
Hoffmann-La Roche
ProHer
Hoffmann-La Roche
KEYNOTE-B15
Merck Sharp & Dohme LLC
A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer
Vaccinogen Inc
INTerpath-005
Merck Sharp & Dohme LLC
neoMono
Palleos Healthcare GmbH
NeoDREAM
Philogen S.p.A.
KEYNOTE-866
Merck Sharp & Dohme LLC
KEYNOTE-905
Merck Sharp & Dohme LLC
KEYNOTE-756
Merck Sharp & Dohme LLC
AEGEAN
AstraZeneca
CheckMate 7FL
Bristol-Myers Squibb
An Observational Study to Learn More About the Impact of Gadoxetate Sodium-Enhanced Magnetic Resonance Imaging (EOB-MRI) When Used to Diagnose the Spread of Cancer From the Pancreas to the Liver in Japanese People Under Real-World Conditions
Bayer
Pivotal
Philogen S.p.A.
FeDeriCa
Hoffmann-La Roche
APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers
Apexigen America, Inc.
NETest_Sx
Wren Laboratories LLC
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.
Qilu Pharmaceutical Co., Ltd.
TP-II
Palleos Healthcare GmbH
PEONY
Hoffmann-La Roche
A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer
Genentech, Inc.
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)
Hoffmann-La Roche
IT-MATTERS
CEL-SCI Corporation
STARS
Accuray Incorporated
Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)
Theraclion
Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC
Eli Lilly and Company
LAPACT
Celgene
AVATAXHER
Hoffmann-La Roche
Post Approval Commitment Study
Endo Pharmaceuticals
INOVA
Hoffmann-La Roche
GBM-Vax
Activartis Biotech
Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)
Merck Sharp & Dohme LLC
Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
INSYS Therapeutics Inc
Treatment With Pazopanib for Neoadjuvant Breast Cancer
GlaxoSmithKline
Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma
Shandong Lanjin Pharmaceuticals Co.,Ltd
rAd-p53
Shenzhen SiBiono GeneTech Co.,Ltd
rAd-p53
Shenzhen SiBiono GeneTech Co.,Ltd
rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors
Shenzhen SiBiono GeneTech Co.,Ltd
Multiple Biomarkers in Undiagnosed Pleural Effusion
Fujirebio Diagnostics, Inc.
Molecular Profiling in Lung Cancer Patients
Eli Lilly and Company
Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Novartis
Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)
Taiho Pharmaceutical Co., Ltd.
A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC)
Taiho Pharmaceutical Co., Ltd.
A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-GC)
Taiho Pharmaceutical Co., Ltd.
IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
INSYS Therapeutics Inc
Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
INSYS Therapeutics Inc
Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
INSYS Therapeutics Inc
Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
INSYS Therapeutics Inc